Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression
Imatinib mesylate is an anti-neoplastic targeted chemotherapeutic agent, which can inhibit tyrosine kinase receptors, including BCR-ABL, platelet-derived growth factor receptors (PDGFRs) and c-Kit. Cellular processes, including differentiation, proliferation and survival are regulated by these recep...
Saved in:
Main Authors: | Kadivar, Ali, Noordin, Mohamed Ibrahim, Aditya, Arya, Kamalidehghan, Behnam, Davoudi, Ehsan Taghizadeh, Sedghi, Reihaneh, Javar, Hamid Akbari |
---|---|
Format: | Article |
Published: |
Spandidos Publications
2018
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/21719/ https://doi.org/10.3892/ijmm.2018.3590 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
[Corrigendum] Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression
by: Kadivar, Ali, et al.
Published: (2019) -
Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes
by: Kadivar, A., et al.
Published: (2017) -
Molecular basis of primary and secondary
resistance to imatinib mesylate
by: Abdul Aziz, Baba
Published: (2012) -
Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience
by: Bee, P.C., et al.
Published: (2006) -
An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia
by: Bee, P.C., et al.
Published: (2012)